14th November 2023 – New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its portfolio of [...]
PRESENTATION TITLE: Late-Breaking Oral Abstract Presentation: NOUS-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome [...]
D’Alise et al, Clin Cancer Res 2024
PRESENTATION TITLE: Nouscom presentation of a Late-Breaking Abstract on Translational Phase 1b data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, at AACR 2023
PRESENTATION TITLE: Nouscom poster presentation on NOUS-PEV Personalized Neoantigen Cancer Vaccine selected for poster presentation at SITC 2022
The aim of personalized cancer vaccines is to elicit potent and tumor-specific immune responses against neoantigens specific to each patient and to establish durable immunity, while minimizing [...]
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
